Exhibit 99.3
LORUS THERAPEUTICS INC.
OFFICER’S CERTIFICATE
TO: | The Securities Commissions in each of the Provinces of Canada |
I, Elizabeth Williams, Director of Finance and Acting Chief Financial Officer of Lorus Therapeutics Inc. (the “Corporation”) hereby certify on behalf of the Corporation and not in my personal capacity that:
1. | this certificate is delivered pursuant to section 2.20 of National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer (“NI 54-101”) and in connection with the mailing of the Corporation’s proxy-related materials for its Annual Meeting to be held on November 30, 2010 (the “Meeting”); |
2. | the Corporation has arranged to have proxy-related materials for the Meeting sent in compliance with NI 54-101 to all beneficial owners at least 21 days before the date fixed for the Meeting; |
3. | the Corporation has arranged to have carried out all of the requirements of NI 54-101 in addition to those prescribed in paragraph 2 above; and |
4. | with respect to the Meeting, the Corporation is relying upon section 2.20 of NI 54-101 to abridge the time prescribed in subsection s. 2.2(1) NI 54-101. |
All defined terms used in this certificate and not otherwise defined shall have the meanings ascribed to such terms in NI 54-101.
Dated this 2nd day of November 2010.
LORUS THERAPEUTICS INC. | ||
By: | “Elizabeth Williams” | |
Elizabeth Williams Director of Finance and Acting Chief Financial Officer |